ADAMTS13 and COVID-19: The time to viral clearance was significantly prolonged in obese patients with low ADAMTS13 activity; the same result was reported by our research team in a previous study.[21] Delayed viral clearance and poor outcomes in obese patients are hallmark findings of several studies.[39,40] Reduced ADAMTS13 activity was one of the most obvious drivers of unmet treatment outcomes in this special patient population, highlighting the importance of rigorous assessment of hospitalized obese COVID-19 patients, regardless of disease severity.